Pharmacogenomics Market
Report ID: SQMIG35H2362
Report ID: SQMIG35H2362
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35H2362 |
Region:
Global |
Published Date: August, 2025
Pages:
191
|Tables:
120
|Figures:
70
Global Pharmacogenomics Market size was valued at USD 3.5 Billion in 2024 and is poised to grow from USD 3.87 Billion in 2025 to USD 8.6 Billion by 2033, growing at a CAGR of 10.5% during the forecast period (2026–2033).
The significant global expansion of the pharmaceutical industry is one of the key factors supporting a positive global pharmacogenomics market outlook. Additionally, the growing need for precision drugs with enhanced drug safety is driving market expansion. As chronic lifestyle diseases become more prevalent, targeted medication therapies with improved efficacy and fewer side effects are being used extensively. As pharmacogenomics is also widely used for cancer treatments and for forecasting possible drug reactions, resistance, efficacy, and toxicity of chemotherapeutic and targeted immune biologic agents, the market is expanding as a result.
What Role Does AI Play in Enhancing Pharmacogenomic Applications?
Artificial intelligence is revolutionizing the global pharmacogenomics sector by expediting and more precisely interpreting genetic data and developing personalized drug therapies. Healthcare professionals utilize AI tools to anticipate drug response in a patient, minimize adverse effects, and provide precise dosing requirements. Baylor College of Medicine researchers developed a generative AI chatbot in August 2024 utilizing GPT-4 and Retrieval-Augmented Generation and used it to help doctors interpret pharmacogenomic test results for statin medications. This study illustrated a mechanism by which AI could accelerate clinical decision-making and expand the relevance of genetic tests in real-world healthcare, which will support a more comprehensive application of pharmacogenomics in precision medicine.
To get more insights on this market click here to Request a Free Sample Report
The global pharmacogenomics market is segmented into product & service, technology, sample type, application, and region. By product & service, the market is divided into instruments, reagents & kits, and software & services. Depending on technology, it is classified into polymerase chain reaction (PCR), DNA sequencing, microarray, mass spectrometry, and electrophoresis. According to sample type, the market is bifurcated into blood and saliva. As per the application, it is categorized into drug discovery & development, oncology, neurology, cardiology, and pain management. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
Why is DNA Sequencing Leading the Pharmacogenomics Industry?
As per the 2024 pharmacogenomics market analysis, the DNA sequencing segment accounts for 32.66% of the market. Its dominance exhibits superior accuracy stemming from declining prices and ability to provide global genetic profiles. DNA sequencing is typically used to identify genetic variants associated with drug response and utilize precision medicine workflows. In 2024, numerous pharmaceutical organizations partnered with sequencing organizations to create patient-specific medications in oncology and neurology applications, dominated and expanded the clinical applications of DNA sequencing.
The microarrays category is anticipated to have the largest pharmacogenomics market share during the projection period, due to affordability and ability to compare hundreds of genetic variants at once. Microarrays are increasingly witnessed in clinical research and population screening approaches. As microarray-based testing is employed in early-sequence drug development by pharmaceuticals, it will typically be adopted faster than other technologies due to commercial feasibility.
What Makes Blood Specimens the Top Contributor to Market Share?
As per the 2024 pharmacogenomics market forecast, 58.47% of the market is made up of blood samples. Their longevity, high DNA yield, and compatibility with the majority of testing platforms account for their extensive use. Pharmacogenomic testing in diagnostic labs and hospitals still typically uses blood samples. Several cancer treatment facilities in the US and Europe cemented their market dominance in 2024 by using blood-based genetic profiling to identify the best chemotherapy regimens.
The saliva segment is anticipated to have the highest compound annual growth rate (CAGR) of 12.40% in the pharmacogenomics sector due to its non-invasiveness, ease of collection, and suitability for at-home testing kits. Patients and healthcare professionals are increasingly using saliva-based diagnostics. By using saliva samples, companies such as 23andMe and Gene by Gene extended their pharmacogenomic services, increasing their accessibility and fostering the expansion of direct-to-consumer genetic testing.
To get detailed segments analysis, Request a Free Sample Report
What Makes North America a Global Hub for Precision Medicine?
As per the pharmacogenomics market regional analysis, North America accounted for 41.91% of the market in 2024, helped along by well-established lab infrastructure, resources for CPIC implementation, and supportive FDA frameworks. Workflow integration blueprints are provided by the University of Colorado and the Mayo Clinic, and the Veterans Affairs program reaches 9 million enrollees. Payer disparity still persists, though, and UnitedHealthcare's 2024 coverage limitations have slowed the uptake of multigene panels.
U.S. Pharmacogenomics Market
The US dominates the pharmacogenomics market because of significant investments in genomics and precision medicine. Pharmacogenomic markers in clinical practice were added to the National Human Genome Research Institute's (NHGRI) All of Us Research Program in March 2025. The United States continues to lead the world in the discovery and use of pharmacogenomics, with a significant uptake among cardiologists and oncologists.
Canada Pharmacogenomics Market
National initiatives are helping the country's pharmacogenomics industry grow. Genome Canada teamed up with healthcare providers in January 2025 to introduce PGx testing in public hospitals, specifically for drugs used to treat cancer and mental health conditions. In significant jurisdictions like British Columbia and Ontario, the incorporation of pharmacogenomics into electronic health records (EHRs) is further driving the field's market expansion and useful clinical application.
What Factors are Fueling Pharmacogenomics Growth in Asia-Pacific?
Asia-Pacific is expected to grow at the fastest rate, with a predicted CAGR of 14.75%. China's Five-Year Health Plan incorporates pharmacogenomic screening into public hospitals and safeguards domestic sequencing supply chains. Indian start-ups like Acrannolife provide PGx bundles for cardiology and psychiatry at local prices. An unmet need was highlighted by a Singapore study that found 46.1% of participants had actionable CYP2D6 alleles. The addition of large population cohorts and diverse haplotypes to biomarker discovery pipelines increases the size of the pharmacogenomics market.
South Korea Pharmacogenomics Market
One of Asia-Pacific's pharmacogenomics hotspots is developing due to government-supported research and development. The Korean National Institute of Health started a PGx project in February 2025 to customize cancer treatment plans using genomic profiling. Scalable adoption is made easier by the nation's sophisticated digital health infrastructure, especially in Seoul's biotech ecosystems and university hospitals.
Japan Pharmacogenomics Market
Japan has a strong position in pharmacogenomics because of its elderly population and loose regulations. A collaboration between Takeda Pharmaceuticals and nearby hospitals to investigate gene-drug interactions in elderly patients was announced in April 2025. The program supports the Japanese Ministry of Health's efforts to include PGx in insurance-covered treatments for heart disease and cancer.
How is Europe Advancing Pharmacogenomics in Public Healthcare?
Europe keeps moving forward as the European Medicines Agency finalized AI-driven pharmacogenomic guidance in 2024, giving manufacturers the clarity they need to scale companion-diagnostic submissions. Population panels are being tested by national health services in France, Germany, and the Nordic countries to quantify long-term cost offsets and promote broader pharmacogenomics market penetration for pharmacogenomics.
UK Pharmacogenomics Market
Pharmacogenomics has been given top priority in the UK's National Health Service (NHS). Pharmacogenomic testing for antidepressants and antiplatelet medications was introduced by NHS England's Genomic Medicine Service in 2025. The UK is positioned as a model for public access to PGx and its integration into standard care due to its statewide implementation, which is backed by Genomics England.
France Pharmacogenomics Market
Through government programs and public-private partnerships, France is hastening the adoption of pharmacogenomics. The French Ministry of Solidarity and Health launched a PGx experiment in March 2025 to customize chemotherapy dosage in hospitals in Paris and Lyon. Data collection and clinical translation of pharmacogenomic discoveries are further facilitated by the growth of genomic research centers such as Inserm.
Germany Pharmacogenomics Market
By integrating with electronic health systems, the country's pharmacogenomics sector is growing. To lessen negative drug effects, Charité-Universitätsmedizin Berlin started a PGx clinical study for anticoagulant treatments in 2025. These efforts, which are being supported by the Federal Ministry of Health, are expanding the clinical utility of pharmacogenomics throughout the German healthcare system.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Pharmacogenomics Market Drivers
Rising Popularity of Personalized Medicine
Genomic Data Integration with EHRs
Pharmacogenomics Market Restraints
Insufficient Consistency and Compensation
Data and Ethics Concerns about Privacy
Request Free Customization of this report to help us to meet your business objectives.
Players in the fiercely competitive industry are concentrating on technology integration and strategic alliances. AI-augmented sequencing systems are being invested in by firms such as Thermo Fisher Scientific and Illumina. Collaborations between genomic labs and pharmaceutical companies have increased; Roche's partnerships with up-and-coming testing companies are one example. To satisfy the increasing demand from customized healthcare providers worldwide, numerous companies are working to obtain regulatory authorization for scaled testing kits and multiplex pharmacogenomic panels
Top Player’s Company Profile
Recent Developments in Pharmacogenomics Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global pharmacogenomics industry is growing at an impressive rate due to several factors, the development of precision medicine, the institutionalization of genomics into practice, and emerging technologies involving artificial intelligence. Adoption accelerated owing to advancements in sequencing, EHR-aligned analytics, and DTC testing. Nevertheless, challenges remain in the form of reimbursement constraints, ethical issues, and data privacy. The industry should have the capability to move rapidly with ongoing collaborations with pharmaceutical companies, healthcare providers, and genomic start-ups. Testing protocol standardization and fostering patient trust in the use of genetic information will be paramount to unlocking its potential. Growth will be particularly encouraged in the areas of cancer, mental health, and chronic conditions.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 3.5 Billion |
| Market size value in 2033 | USD 8.6 Billion |
| Growth Rate | 10.5% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
Top Player’s Company Profile
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Pharmacogenomics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Pharmacogenomics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Pharmacogenomics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Pharmacogenomics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
